More on URGN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (6.9 Score)

Upcoming Events

- Earnings (8/7/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

UroGen Pharma (NQ:URGN)
Delayed: 20.46 +0.85 (4.33%)
Prev. Close $19.61  
Open$19.10 
52 Wk High$ 
52 Wk Low$ 
Day High$20.82 
Day Low$18.68 
P/E N/A  
EPS$ 
Volume1,226,375 

Friends, Peers and Foes (?): ABBV, ARGX, ARWR, BBIO, CGON (more...)

Mar 6, 2026 04:10 PM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 3, 2026 07:31 AM UroGen Pharma (URGN) PT Raised to $34 at Oppenheimer
Mar 2, 2026 11:20 AM Oppenheimer Reiterates Outperform Rating on UroGen Pharma (URGN) "We Buy the Weakness"
Mar 2, 2026 08:40 AM UroGen Pharma (URGN) Misses Q4 EPS by 6c
Mar 2, 2026 08:11 AM Form 10-K UroGen Pharma Ltd. For: Dec 31
Mar 2, 2026 08:09 AM Form 8-K UroGen Pharma Ltd. For: Mar 02
Mar 2, 2026 08:06 AM Form 8-K UroGen Pharma Ltd. For: Feb 26
Mar 2, 2026 08:04 AM UroGen launches ZUSDURI as revenue rises 21% in 2025
Mar 2, 2026 08:00 AM UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 2, 2026 07:55 AM UroGen refinances debt with Pharmakon at 8.25% fixed rate
View All Articles

Entities mentioned with URGN

View All Entities